同和药业替格瑞洛原料药变更后获CEP证书

Core Viewpoint - The company, Tonghe Pharmaceutical, has received an updated Certificate of Suitability (CEP) from the European Medicines Agency for its raw material drug, Ticagrelor, due to the addition of a new production facility, effective from September 12, 2025 [1] Group 1: Company Information - Tonghe Pharmaceutical announced the receipt of the updated CEP for Ticagrelor, a novel selective small-molecule anticoagulant [1] - The updated certificate is a result of the company's expansion with a new production workshop [1] Group 2: Product Details - Ticagrelor is designed to block platelet activation, used for treating acute coronary syndrome patients, and aims to reduce the occurrence of thrombotic cardiovascular diseases [1] - The drug is characterized by its rapid and potent effects [1]